Reply to Dr Pond et al.

Smith, Dwight L.

doi:10.1016/0954-6111(95)90169-8

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, this univariate situation has been explored and evaluated in a very wide variety of modelling situations and statistical paradigms. For example, the Bayesian models of Carlin [1] and Smith et al [2] may be contrasted with the generalized linear mixed model approach of Platt et al [3], while Mengersen et al [4] and Brockwell and Gordon [5] examine more general questions of method choice. In particular, the two latter papers ÿnd favour with models that admit between-study heterogeneity (random e ects models) but demonstrate concerns about the coverage probabilities of some methods commonly used in practice.…”

Section: Introductionmentioning

confidence: 99%

Multivariate meta‐analysis

Nam

Mengersen

Garthwaite

2003

Statistics in Medicine

125

148

View full text Add to dashboard Cite

Meta-analysis is now a standard statistical tool for assessing the overall strength and interesting features of a relationship, on the basis of multiple independent studies. There is, however, recent acknowledgement of the fact that in many applications responses are rarely uniquely determined. Hence there has been some change of focus from a single response to the analysis of multiple outcomes. In this paper we propose and evaluate three Bayesian multivariate meta-analysis models: two multivariate analogues of the traditional univariate random effects models which make different assumptions about the relationships between studies and estimates, and a multivariate random effects model which is a Bayesian adaptation of the mixed model approach. Our preferred method is then illustrated through an analysis of a new data set on parental smoking and two health outcomes (asthma and lower respiratory disease) in children.

show abstract

Section: Introductionmentioning

confidence: 99%

Multivariate meta‐analysis

Nam

Mengersen

Garthwaite

2003

Statistics in Medicine

125

148

View full text Add to dashboard Cite

show abstract

“…antagonists aprepitant (pK i 10.1)[915,916], CP 99994 (pK i 9.3-9.7)[66,2269], RP67580 (pIC 50 7.7)[711] GR94800 (pK i 9.8)[264], saredutant (pK i 9.4-9.7)[66,650,2269], GR 159897 (pK d 7.8-9.5)[182,650,2417], MEN10627 (pK i 9.2)[812], nepadutant (pK i 8.5-8.7)[361,460] osanetant (pK i 8 4. 9.7) [66, 152, 459, 649, 1206, 1965, 2268, 2269, 2580], talnetant (pK i 7.4-9) [176, 813, 2268, 2269], PD157672 (pIC 50 7.8-7.9) [219, 2580] Labelled ligands [ 125 I]L703,606 (Antagonist) (pK d 9.5) [723], [ 125 I] BH-[Sar9,Met(O2)11]SP (Agonist) [2606] -Rat, [ 3 H]SP (human, mouse, rat) (Agonist) [112], [ 125 I]SP (human, mouse, rat) (Agonist), [ 18 F]SPA-RQ (Antagonist) [430] [ 3 H]saredutant (Antagonist) (pK d 9.7) [878] -Rat, [ 125 I]NKA (human, mouse, rat) (Agonist) [2745], [ 3 H] GR100679 (Antagonist) (pK d 9.2) [911]…”

mentioning

confidence: 99%

The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors

Alexander,

Christopoulos,

Davenport

et al. 2023

British J Pharmacology

View full text Add to dashboard Cite

The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and about 6000 interactions with about 3900 ligands. There is an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (https://www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes almost 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/bph.16177. G protein‐coupled receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2023, and supersedes data presented in the 2021/22, 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

show abstract

Reply to Dr Pond et al.

Cited by 2 publications

References 0 publications

Multivariate meta‐analysis

Multivariate meta‐analysis

The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors

Contact Info

Product

Resources

About